XY0206 versus standard chemotherapy for relapsed or refractory AML with FLT3-ITD mutation
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares a new targeted pill (XY0206) with standard chemotherapy for people whose acute myeloid leukemia (AML) has come back or not responded to earlier treatment. The drug specifically targets cancers with a certain genetic change (FLT3-ITD) and may offer a more tailored option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acute myeloid leukemia (AML) that has returned or did not respond to previous treatment.
- Your leukemia has a specific genetic marker called FLT3-ITD (confirmed by a blood or bone marrow test).
- You are able to take care of yourself (ECOG performance status 0, 1, or 2).
- Your liver and kidney function are within acceptable levels.
- You have not had a stem cell transplant in the past 2 months and do not have active graft-versus-host disease.
- You have not had certain other cancers or treatments that would interfere.
- You are not pregnant or breastfeeding and agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, SNDX-5613 and gilteritinib, for people whose AML has come back or hasn't responded to treatment. It is for those with an FLT3 gene mutation plus another specific genetic change like NPM1 or MLL. The study aims to see if this two-drug approach works better when used together.
This trial tests a new combination of medications against a standard treatment for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3-ITD mutation. The goal is to find out if the new combination works better and has fewer side effects. If you have this type of AML, you might be able to join and get access to newer drugs.
This Phase 3 study compares HEC73543 versus standard “salvage” chemotherapy in adults with AML that has come back or did not respond after first treatment. It’s designed for people whose leukemia has an FLT3-ITD mutation and may help improve response and outcomes.
This trial tests a targeted therapy that specifically attacks leukemia cells with the FLT3-ITD gene change. If you have this mutation, the goal is to see if adding this drug to standard chemotherapy improves your chances of going into remission.
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
This study tests clifutinib (a targeted medicine) combined with chemotherapy in people newly diagnosed with AML. It aims to see if this combination is safer and more effective, including in older adults and people who may not tolerate strong chemotherapy.
Hear when a new Acute Myeloid Leukemia With FLT3/ITD Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.